 | • レポートコード：MRC2301A103 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、239ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査資料では、2021年に2,002.5億ドルであった世界の医薬品有効成分（API）市場規模が、2022年には2,130.8億ドルになり、その後CAGR 6.58％で拡大して2027年まで2,936.5億ドルに達すると予想されています。当書は、医薬品有効成分（API）の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（ジェネリックAPI、革新的API）分析、合成別（バイオテクノロジーAPI、合成API）分析、製造者別（内製APIメーカー、外販APIメーカー）分析、治療用途別（心血管疾患、伝染病、糖尿病、腫瘍、疼痛管理）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめています。なお、当書に掲載されている企業情報には、Abbvie Inc.、API Pharma Tech、Astrazeneca、Aurobindo Pharma、BASF SE、BDR Pharmaceuticals Internationals Pvt. Ltd.、Boehringer Ingelheim、Bristol-Myers Squibb、Cipla, Inc.、Dr. Reddy's Laboratories Ltd、ELI Lilly and Company、F. Hoffmann-La Roche、Glaxosmithkline PLC、Merck & Co., Inc.、Mylan N.V.、Novartis AG、Pfizer, Inc.、Sanofi、Sun Pharmaceutical Industries Ltd、Teva Pharmaceutical Industries Ltdなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の医薬品有効成分（API）市場規模：種類別 - ジェネリックAPIの市場規模 - 革新的APIの市場規模 ・世界の医薬品有効成分（API）市場規模：合成別 - バイオテクノロジーAPIの市場規模 - 合成APIの市場規模 ・世界の医薬品有効成分（API）市場規模：製造者別 - 内製APIメーカーの市場規模 - 外販APIメーカーの市場規模 ・世界の医薬品有効成分（API）市場規模：治療用途別 - 心血管疾患における市場規模 - 伝染病における市場規模 - 糖尿病における市場規模 - 腫瘍における市場規模 - 疼痛管理における市場規模 ・世界の医薬品有効成分（API）市場規模：地域別 - 南北アメリカの医薬品有効成分（API）市場規模 アメリカの医薬品有効成分（API）市場規模 カナダの医薬品有効成分（API）市場規模 ブラジルの医薬品有効成分（API）市場規模 ... - アジア太平洋の医薬品有効成分（API）市場規模 日本の医薬品有効成分（API）市場規模 中国の医薬品有効成分（API）市場規模 インドの医薬品有効成分（API）市場規模 韓国の医薬品有効成分（API）市場規模 台湾の医薬品有効成分（API）市場規模 ... - ヨーロッパ/中東/アフリカの医薬品有効成分（API）市場規模 イギリスの医薬品有効成分（API）市場規模 ドイツの医薬品有効成分（API）市場規模 フランスの医薬品有効成分（API）市場規模 ロシアの医薬品有効成分（API）市場規模 ... - その他地域の医薬品有効成分（API）市場規模 ・競争状況 ・企業情報 |
The Global Active Pharmaceutical Ingredients Market size was estimated at USD 200.25 billion in 2021 and expected to reach USD 213.08 billion in 2022, and is projected to grow at a CAGR 6.58% to reach USD 293.65 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Active Pharmaceutical Ingredients to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Generic Active Pharmaceutical Ingredients and Innovative Active Pharmaceutical Ingredients.
Based on Synthesis, the market was studied across Biotech Active Pharmaceutical Ingredients and Synthetic Active Pharmaceutical Ingredients.
Based on Manufacturer, the market was studied across Captive API Manufacturers and Merchant API Manufacturers.
Based on Therapeutic Application, the market was studied across Cardiovascular Diseases, Communicable Diseases, Diabetes, Oncology, Pain Management, and Respiratory Diseases.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Active Pharmaceutical Ingredients market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Active Pharmaceutical Ingredients Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Active Pharmaceutical Ingredients Market, including Abbvie Inc., API Pharma Tech, Astrazeneca, Aurobindo Pharma, BASF SE, BDR Pharmaceuticals Internationals Pvt. Ltd., Boehringer Ingelheim, Bristol-Myers Squibb, Cipla, Inc., Dr. Reddy’s Laboratories Ltd, ELI Lilly and Company, F. Hoffmann-La Roche, Glaxosmithkline PLC, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer, Inc., Sanofi, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Active Pharmaceutical Ingredients Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Active Pharmaceutical Ingredients Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Active Pharmaceutical Ingredients Market?
4. What is the competitive strategic window for opportunities in the Global Active Pharmaceutical Ingredients Market?
5. What are the technology trends and regulatory frameworks in the Global Active Pharmaceutical Ingredients Market?
6. What is the market share of the leading vendors in the Global Active Pharmaceutical Ingredients Market?
7. What modes and strategic moves are considered suitable for entering the Global Active Pharmaceutical Ingredients Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of chronic diseases
5.1.1.2. Growing importance of generics coupled with uptakes of biopharmaceuticals
5.1.1.3. Technological advancements in active pharmaceutical ingredients
5.1.1.4. Adoption of AI-based tools and organ-on-chip models in drug discovery & development
5.1.1.5. Rising focus on precision medicine and growing investment
5.1.2. Restraints
5.1.2.1. Unsupportive price control policies for drug across various countries
5.1.2.2. Increasing availability of counterfeit drugs
5.1.3. Opportunities
5.1.3.1. Emergence of biosimilars
5.1.3.2. Highly effective active pharmaceutical ingredients
5.1.4. Challenges
5.1.4.1. High cost associated with the manufacturing process
5.1.4.2. Concern associated with the product differentiation
5.2. Cumulative Impact of COVID-19
6. Active Pharmaceutical Ingredients Market, by Type
6.1. Introduction
6.2. Generic Active Pharmaceutical Ingredients
6.3. Innovative Active Pharmaceutical Ingredients
7. Active Pharmaceutical Ingredients Market, by Synthesis
7.1. Introduction
7.2. Biotech Active Pharmaceutical Ingredients
7.3. Synthetic Active Pharmaceutical Ingredients
8. Active Pharmaceutical Ingredients Market, by Manufacturer
8.1. Introduction
8.2. Captive API Manufacturers
8.3. Merchant API Manufacturers
9. Active Pharmaceutical Ingredients Market, by Therapeutic Application
9.1. Introduction
9.2. Cardiovascular Diseases
9.3. Communicable Diseases
9.4. Diabetes
9.5. Oncology
9.6. Pain Management
9.7. Respiratory Diseases
10. Americas Active Pharmaceutical Ingredients Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Active Pharmaceutical Ingredients Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Active Pharmaceutical Ingredients Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbvie Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. API Pharma Tech
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Astrazeneca
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Aurobindo Pharma
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. BASF SE
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. BDR Pharmaceuticals Internationals Pvt. Ltd.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Boehringer Ingelheim
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Bristol-Myers Squibb
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Cipla, Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Dr. Reddy’s Laboratories Ltd
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. ELI Lilly and Company
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. F. Hoffmann-La Roche
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Glaxosmithkline PLC
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Merck & Co., Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Mylan N.V.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Novartis AG
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Pfizer, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Sanofi
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Sun Pharmaceutical Industries Ltd
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Teva Pharmaceutical Industries Ltd
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing